Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2024Open Access

Use of Eltrombopag to Improve Thrombocytopenia and Transfusion Requirement in Anti-CD19 Car-T Cell-Treated Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaría Eva Mingot‐CastellanoInstituto de Biomedicina de SevillaJRJuan Luis RegueraHospital Universitario Virgen del RocíoDTD. Zafra TorresHospital Universitario 12 De Octubre

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mingot‐Castellano et al. (2024) studied this question.

synapsesocial.com/papers/68e5e8feb6db64358757e226https://doi.org/10.20944/preprints202407.2382.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients2024 · 3 citations
  2. 2Eltrombopag for Chemotherapy-Induced Thrombocytopenia: A Multicenter Retrospective Real-World Study2026 · 1 citations
  3. 3Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases2014 · 4 citations
  4. 4TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience2025
  5. 5Comparative study of hetrombopag vs. eltrombopag in promoting platelet engraftment post-autologous hematopoietic stem cell transplantation: A multicenter clinical trial2025